06 Oct 2026, 08:47 IST
Divi's Laboratories Limited
Motilal Oswal Financial Services Ltd. (MOFSL) · BUY · target ₹10,800
The report recommends BUY on Divi's Laboratories with CMP ₹9,540, TP ₹10,800 and SL ₹8,870, citing peptide API demand from oral Wegovy, favorable US tariff clarity under Proclamation 11020, and expected 21% earnings CAGR over FY26-28.
From MOStMarketOutlook06102026, written by Motilal Oswal Financial Services Ltd. (MOFSL) and hosted by Investment Guru India. Orivam summarised it; the view is Motilal Oswal Financial Services Ltd. (MOFSL)'s, not Orivam's.
Open the original PDF on Investment Guru India →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.